Add Presentation to Slide Tray Presentation:
Drug Therapy for Rheumatoid Arthritis in Adults
Authors: John I. Gomez, MD
Summary of Benefits: Combination Treatments With Oral DMARDs
The comparative benefits of combination treatments with oral disease-modifying anti-rheumatic drugs (DMARDs) may be summarized as follows:
- In patients with longstanding active rheumatoid arthritis (RA), combining up to three oral DMARDs (methotrexate [MTX], sulfasalazine, and hydroxychloroquine) produces greater improvements in disease activity than one or two oral DMARDs. The strength of evidence for this finding is moderate.
- For patients with early RA who have not previously been treated with oral DMARDs, combining oral DMARDs (sulfasalazine and MTX) does not improve symptom response, radiographic progression, or functional capacity more than monotherapy. The strength of evidence for this finding is moderate.
Keywords: anti-rheumatic | antirheumatic | biologic DMARD | disease activity | disease-modifying | DMARDs | early RA | functional capacity | hydroxychloroquine | methotrexate | nonbiologic DMARD | oral DMARD | RA | radiographic progression | rheumatic | sulfasalazine | symptom response | rheumatoid arthritis
- Donahue KE, Jonas D, Hansen RA, et al. Drug Therapy for Rheumatoid Arthritis in Adults: An Update. Comparative Effectiveness Review No. 55 (Prepared by the RTI International–University of North Carolina Evidence-based Practice Center under Contract No. 290-2007-10056-I). Rockville, MD: Agency for Healthcare Research and Quality; April 2012. AHRQ Publication No. 12-EHC025-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsra.cfm.
Your slide tray is being processed.